S13-1 Current analysis and prospects of new toxicological biomarkers : with central focus on heart, liver and kidney(SYMPOSIUM 13: CURRENT STATUS AND FUTURE ASPECTS OF NEW TOXICOLOGICALLY RESPONSIBLE BIOMARKERS)(Proceedings of the 31st Annual Meeting)
スポンサーリンク
概要
- 論文の詳細を見る
- 日本トキシコロジー学会の論文
- 2004-10-29
著者
-
Sagami Fumio
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
NAITO Shinsaku
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
Amano Yukinori
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
TANAKA Takeshi
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
YOSHIOKA Kaoru
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
TAKAHASHI Koichi
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
DODO Tetsushi
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
KURODA Satoko
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
UEYAMA Seiichi
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
ASANOMA Koji
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
MATSUZAWA Toshiaki
Subcommittee of Non-Clinical Evaluation, Drug Evaluation Committee, Japan Pharmaceutical Manufacture
-
Asanoma Koji
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Dodo Tetsushi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Kuroda Satoko
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Yoshioka Kaoru
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Ueyama Seiichi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Naito Shinsaku
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Matsuzawa Toshiaki
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Sagami Fumio
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Tanaka Takeshi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
-
Takahashi Koichi
Subcommittee Of Non-clinical Evaluation Drug Evaluation Committee Japan Pharmaceutical Manufacturers
関連論文
- Collaborative work on evaluation of ovarian toxicity by repeated-dose and fertility studies in female rats
- Safety assessment of biopharmaceuticals : Japanese perspective on ICH S6 guideline maintenance
- Points to consider on the non-clinical safety evaluation of anticancer drugs
- CURRENT OPINION : SAFETY EVALUATION OF DRUG METABOLITES IN DEVELOPMENT OF PHARMACEUTICALS
- "POINTS TO CONSIDER" REGARDING SAFETY ASSESSMENT OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS IN NON-CLINICAL STUDIES (ENGLISH TRANSLATION)
- Current status of pharmaceutical industries in Japan on pharmacogenomics and toxicogenomics in 2005(Toxicogenomics, Toxicoproteomics, Proceedings of the 32nd Annual Meeting)
- S3-6 Problems and Meanings of Genome-based Drug Discovery in Japanese Pharmaceutical Companies(SYMPOSIUM 3: BENEFITS OF PHARMACOGENOMICS/PHARMACOGENETICS IN PHARMACEUTICAL DEVELOPMENT)(Proceedings of the 31st Annual Meeting)
- P7-39 Current Analysis and Prospects of New Toxicological Biomarker : Biomarkers of Hepatotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- P7-38 Current analysis and prospects of new toxicological biomarker : biomarkers of cardiotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- P7-37 Current Analysis and Prospects of New Toxicological Biomarker : Biomarkers of Nephrotoxicity(GENERAL TOXICITY)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- S13-1 Current analysis and prospects of new toxicological biomarkers : with central focus on heart, liver and kidney(SYMPOSIUM 13: CURRENT STATUS AND FUTURE ASPECTS OF NEW TOXICOLOGICALLY RESPONSIBLE BIOMARKERS)(Proceedings of the 31st Annual Meeting)
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 3. LOW MOLECULAR WEIGHT ELICITOGENIC ANTIGENS OF IODINE ALLERGY
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 2. IODINATED PROTEIN ANTIGENS AND THEIR GENERATION FROM INORGANIC AND ORGANIC IODINE-CONTAINING CHEMICALS
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 1. ANTIGEN RECOGNITION OF GUINEA PIG ANTI-IODINE ANTIBODY
- P-11 Application of hepatocytes cultured in a sandwich configuration to toxicity assessment.(Proceedings of the 27th Annual Meeting)
- Mechanism for benzothiazole derivative-induced hepatotoxicity in rats(SYMPOSIUM 1 : MECHANISMS OF HEPATOTOXIC EFFECTS)
- P-90 Collaborative Work to Evaluate Toxicity on Male Reproductive Organs with 2 Weeks Repeated Daily Dosing in Rats : Testicular Toxicity of E7010, A Sulfonamide Tubulin Polymerlzation Inhibitor(Proceedings of the 27th Annual Meeting)
- COLLABORATIVE WORK TO EVALUATE TOXICITY ON MALE REPRODUCTIVE ORGANS BY REPEATED DOSE STUDIES IN RATS : 17)TESTICULAR TOXICITY OF E7010, A SULFONAMIDE TUBULIN POLYMERIZATION INHIBITOR
- TOXICOLOGICAL RESPONSE OF RATS TO A NOVEL MONOAMINE OXIDASE TYPE-A INHIBITOR, (5R)-3-[2-((1S)-3-CYANO-1-HYDROX-YPROPYL)BENZOTHIAZOL-6-YL]-5-METHOXYMETHYL-2-OXAZOLIDI-NONE (E2011), ORALLY ADMINISTERED FOR 13 WEEKS
- "B-5 Modification of Drug Conjugation Pathway by Repeated Administration of Conjugating Enzyme Inhibitors in Rats.
- P11-12 Questionnaire Survey of Functional Observational Battery in Pharmaceutical Industries in Japan.